ZYNERBA PHARMACEUTICALS INC's ticker is ZYNE and the CUSIP is 98986X109. A total of 65 filers reported holding ZYNERBA PHARMACEUTICALS INC in Q4 2017. The put-call ratio across all filers is 0.96 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $258 | – | 46 | – | 0.00% | – |
| Q2 2021 | $0 | – | 0 | – | 0.00% | – |
| Q1 2021 | $0 | -100.0% | 0 | -100.0% | 0.00% | – |
| Q1 2019 | $3,000 | +200.0% | 500 | +13.6% | 0.00% | – |
| Q4 2018 | $1,000 | -75.0% | 440 | 0.0% | 0.00% | – |
| Q3 2018 | $4,000 | 0.0% | 440 | 0.0% | 0.00% | – |
| Q2 2018 | $4,000 | -42.9% | 440 | -25.4% | 0.00% | – |
| Q1 2018 | $7,000 | 0.0% | 590 | 0.0% | 0.00% | – |
| Q4 2017 | $7,000 | +16.7% | 590 | -14.5% | 0.00% | – |
| Q3 2017 | $6,000 | -68.4% | 690 | -37.6% | 0.00% | -100.0% |
| Q2 2017 | $19,000 | +72.7% | 1,105 | +104.6% | 0.00% | – |
| Q1 2017 | $11,000 | -82.0% | 540 | -86.2% | 0.00% | -100.0% |
| Q4 2016 | $61,000 | +144.0% | 3,900 | +105.3% | 0.00% | +200.0% |
| Q3 2016 | $25,000 | +525.0% | 1,900 | +216.7% | 0.00% | – |
| Q2 2016 | $4,000 | +33.3% | 600 | +20.0% | 0.00% | – |
| Q1 2016 | $3,000 | – | 500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ETF MANAGERS GROUP, LLC | 2,679,457 | $20,257,000 | 0.73% |
| Portolan Capital Management | 777,293 | $5,876,000 | 0.66% |
| CAMPBELL CAPITAL MANAGEMENT INC | 110,451 | $835,000 | 0.62% |
| ZEKE CAPITAL ADVISORS, LLC | 402,212 | $3,041,000 | 0.27% |
| Leap Investments LP | 46,084 | $348,000 | 0.17% |
| Bernardo Wealth Planning LLC | 26,419 | $199,000 | 0.14% |
| Claraphi Advisory Network, LLC | 14,744 | $111,000 | 0.07% |
| Sterling Investment Advisors, Ltd. | 11,000 | $83,000 | 0.04% |
| A.R.T. Advisors, LLC | 81,372 | $615,000 | 0.03% |
| Mirae Asset Global Investments Co., Ltd. | 544,408 | $4,116,000 | 0.03% |